Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TNGX

Tango Therapeutics Inc

31.06

Jul 10 • 04:00PM ET +0.54 (1.77%)

Healthcare Biotechnology USA Mid NASD

Peers: CGON KYMR NUVL BMRN INCY RYTM APGE KRYS AXSM NBIX

| Held by: IWM XBI VTI IWO IBB VXF SCHA VTWO FESM FYC

Scroll to Statements

Index	RUT
Market Cap	5.06B
Enterprise Value	4.71B
Income	-107.23M
Sales	56.99M
Book/sh	2.72
Cash/sh	2.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	137
IPO	Sep 03, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	88.74
P/B	11.44
P/C	13.31
P/FCF	-
EV/EBITDA	-
EV/Sales	82.65
Quick Ratio	27.38
Current Ratio	27.38
Debt/Eq	0.08
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-0.82
EPS next Y	-1.54
EPS next Q	-0.32
EPS this Y	-49.43%
EPS next Y	-18.53%
EPS next 5Y	-24.36%
EPS past 3/5Y	10.79% 11.68%
Sales past 3/5Y	35.89% 52.13%
EPS Y/Y TTM	32.40%
Sales Y/Y TTM	39.04%
EPS Q/Q	12.31%
Sales Q/Q	-100.00%
Earnings	May 13 AMC
EPS/Sales Surpr.	-2.01% -100.00%

Insider Own	26.72%
Insider Trans	-0.67%
Inst Own	89.11%
Inst Trans	1.28%
ROA	-30.20%
ROE	-38.42%
ROIC	-25.44%
Gross Margin	96.28%
Oper. Margin	-206.22%
Profit Margin	-188.15%
SMA20	2.17%
SMA50	20.13%
SMA200	94.60%
Trades

Shs Outstand	144.16M
Shs Float	119.32M
Short Float	35.21%
Short Ratio	9.95
Short Interest	42.01M
52W High	34.39 -9.68%
52W Low	5.75 440.17%
Volatility	6.22% 6.99%
ATR (14)	2.13
RSI (14)	58.01
Beta	1.15
Rel Volume	0.80
Avg Volume	4.22M
Volume	3,371,933

Perf Week	5.43%
Perf Month	-1.58%
Perf Quarter	50.05%
Perf Half Y	163.44%
Perf YTD	250.56%
Perf Year	408.35%
Perf 3Y	870.62%
Perf 5Y	184.50%
Perf 10Y	-
Recom	1.17
Target Price	43.82
Prev Close	30.52
Price	31.06
Change	1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-26	Upgrade	Jefferies	Hold → Buy	$60
Jun-08-26	Upgrade	Wolfe Research	Peer Perform → Outperform
May-15-26	Downgrade	Piper Sandler	Overweight → Neutral	$24
May-14-26	Downgrade	Jefferies	Buy → Hold	$27
Apr-02-26	Initiated	Canaccord Genuity	Buy	$30
Feb-23-26	Initiated	Mizuho	Outperform	$19
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Aug-19-25	Initiated	Piper Sandler	Overweight	$11
Jul-17-24	Initiated	Jefferies	Buy	$19
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight	$18
Dec-08-23	Initiated	B. Riley Securities	Buy	$16
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Sep-20-21	Initiated	SVB Leerink	Outperform	$25

Show Previous Ratings

Jun-26-26 03:38PM	This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In. (Barrons.com)
Jun-22-26 04:05PM	Tango Therapeutics Appoints Robert Azelby to Board of Directors (GlobeNewswire)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
Jun-09-26 10:49PM	Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering (GlobeNewswire) -9.13%
09:32AM	Tango Therapeutics stock surges on pancreatic cancer drug combo data (Quartz)
09:31AM	Loading…
09:31AM	Tango Therapeutics stock surges on pancreatic cancer trial data (Quartz)
Jun-08-26 04:09PM	Tango Skyrockets On Eye-Popping Pancreatic Cancer Results (Investor's Business Daily) +52.97%
04:01PM	Tango Therapeutics Announces Proposed $500 Million Public Offering (GlobeNewswire)
02:28PM	?? Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data (The Wall Street Journal)
01:44PM	TNGX Stock Hits All-Time High Wolfe Research Calls Tango Therapeutics Pancreatic Cancer Trial Data Groundbreaking (Stocktwits)
12:28PM	Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment (Barrons.com)
06:59AM	Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer (GlobeNewswire)
Jun-05-26 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.71%
May-13-26 04:07PM	Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire) +8.55%
May-04-26 04:31PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.25% +6.56%
08:03AM	Loading…
Apr-30-26 08:03AM	Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results (Investor's Business Daily)
Apr-15-26 09:05AM	Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat (GlobeNewswire) +5.28%
Mar-10-26 08:03AM	Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) (Insider Monkey)
Mar-09-26 11:15AM	X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention (24/7 Wall St.)
Mar-07-26 08:20PM	Tango Therapeutics (TNGX) Soars 52% on Buy Reco (Insider Monkey)
Mar-06-26 05:33PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:45AM	TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS (Zacks)
Mar-05-26 08:13PM	Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish (Insider Monkey) +36.28%
04:13PM	Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact (Investor's Business Daily)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-04-26 07:18AM	Earnings To Watch: Tango Therapeutics Inc (TNGX) Reports Q4 2025 Result (GuruFocus.com) +7.39%
Feb-26-26 09:38AM	RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View (Zacks) -9.74%
Feb-18-26 07:00AM	Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-15-26 02:02PM	Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat (MarketBeat)
Feb-03-26 07:00AM	Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) +5.11%
09:05AM	Loading…
Jan-08-26 09:05AM	Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor (GlobeNewswire) -6.23%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +21.92%
Jan-05-26 07:00AM	Tango Therapeutics Appoints Sung Lee to Board of Directors (GlobeNewswire)
Dec-22-25 08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
07:00AM	Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-08-25 09:55AM	Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-26-25 07:00AM	Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-21-25 07:45PM	Novavax, UniFirst, and More Stocks See Action From Activist Investors (Barrons.com) +12.70%
09:55AM	Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? (Zacks)
Nov-12-25 07:00AM	Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -8.47%
Nov-04-25 10:15AM	Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates (Zacks)
09:00AM	Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-03-25 07:46AM	Tango Therapeutics Inc (TNGX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-31-25 09:55AM	Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet (Zacks)
Oct-29-25 07:00AM	Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-27-25 12:00PM	Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why (Zacks)
Oct-23-25 07:20AM	Tango Therapeutics Announces $225 Million Financing (GlobeNewswire) -13.05%
07:00AM	Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers (GlobeNewswire)
Oct-06-25 07:00AM	Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (GlobeNewswire)
Sep-17-25 09:27AM	Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? (Zacks)
Aug-26-25 07:00AM	Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-19-25 09:32AM	Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Aug-04-25 09:53AM	Tango Therapeutics Inc (TNGX) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 07:40PM	IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates (Zacks) +8.11%
Jul-30-25 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:55AM	Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade (Zacks)
Jul-29-25 10:00AM	Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-22-25 07:00AM	Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
Jul-14-25 09:55AM	Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? (Zacks)
Jun-30-25 05:47AM	Tango doses first subject in MTAP-deleted and RAS mutant cancer trial (Clinical Trials Arena)
Jun-27-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer (GlobeNewswire)
Jun-23-25 09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
May-27-25 07:00AM	Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire) +11.41%
May-21-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors (GlobeNewswire) -8.70%
May-12-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +14.91%
07:00AM	Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
May-09-25 09:45AM	Tango Therapeutics Inc (TNGX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-06-25 08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -11.27%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.96%
May-01-25 07:00AM	Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +16.53%
Mar-25-25 04:30PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.75% -6.10%
Feb-27-25 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -6.44%
Feb-20-25 07:30AM	Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference (GlobeNewswire)
Dec-03-24 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.14%
Nov-27-24 07:00AM	Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +6.25%
Nov-23-24 10:26AM	Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-06-24 07:05AM	Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (Business Wire) -37.45%
07:00AM	Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program (Business Wire)
Aug-28-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-18-24 09:03AM	Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks (TipRanks)
Aug-07-24 07:00AM	Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
Jun-14-24 05:10AM	Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.44%
Jun-05-24 07:00AM	Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-23-24 09:18AM	Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program (PR Newswire)
07:00AM	Tango Therapeutics Announces Discontinuation of TNG348 Program (Business Wire)
May-08-24 01:53PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
May-07-24 10:00AM	Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-01-24 04:48PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-20-24 05:31AM	Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-18-24 02:52PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.09%
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights (Business Wire)

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.

Founder & Executive Chairman of the BoardDr. Barbara L. Weber M.D.

PresidentDr. Malte Peters M.D.

Executive OfficerMs. Daniella Beckman CPA

Ph.D.Dr. Adam S. Crystal M.D.

Ph.D.Prof. Alan Ashworth FRS

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crystal Adam	President, R&D	Jul 01 '26	Option Exercise	5.20	27,000	140,400	142,743	Jul 02 07:23 PM
Crystal Adam	President, R&D	Jul 01 '26	Sale	29.59	27,000	798,908	115,743	Jul 02 07:23 PM
Nextech Crossover I SCSp	Former Affiliate	Jun 17 '26	Proposed Sale	30.10	3,766,081	113,359,038		Jun 17 04:45 PM
DANIELLA BECKMAN	Officer	Jun 11 '26	Proposed Sale	28.76	1,791,726	51,523,582		Jun 11 06:00 PM
DANIELLA BECKMAN	Officer	Jun 10 '26	Proposed Sale	30.00	4,446	133,380		Jun 10 04:45 PM
Crystal Adam	President, R&D	Jun 01 '26	Option Exercise	5.20	27,000	140,400	142,743	Jun 03 06:37 PM
Crystal Adam	President, R&D	Jun 01 '26	Sale	22.87	27,000	617,571	115,743	Jun 03 06:37 PM
Crystal Adam	President, R&D	May 01 '26	Option Exercise	5.20	27,000	140,400	142,743	May 05 07:47 PM
Crystal Adam	President, R&D	May 01 '26	Sale	21.23	27,000	573,097	115,743	May 05 07:47 PM
ADAM CRYSTAL	Officer	May 01 '26	Proposed Sale	21.62	65,460	1,415,245		May 01 04:48 PM
Crystal Adam	President, R&D	Apr 15 '26	Option Exercise	5.20	38,460	199,992	151,082	Apr 16 08:14 PM
Crystal Adam	President, R&D	Apr 15 '26	Sale	25.00	38,460	961,500	112,622	Apr 16 08:14 PM
Crystal Adam	President, R&D	Apr 01 '26	Option Exercise	5.20	27,000	140,400	139,622	Apr 02 08:09 PM
Crystal Adam	President, R&D	Apr 01 '26	Sale	21.20	27,000	572,478	112,622	Apr 02 08:09 PM
Crystal Adam	President, R&D	Mar 25 '26	Option Exercise	5.20	12,000	62,400	124,622	Mar 27 08:06 PM
Crystal Adam	President, R&D	Mar 25 '26	Sale	20.11	12,000	241,320	112,622	Mar 27 08:06 PM
ADAM CRYSTAL	Officer	Mar 25 '26	Proposed Sale	19.48	93,000	1,811,640		Mar 25 04:24 PM
Crystal Adam	President, R&D	Mar 05 '26	Sale	15.00	20,251	303,765	112,622	Mar 09 04:01 PM
ADAM CRYSTAL	Officer	Mar 05 '26	Proposed Sale	12.35	20,251	250,100		Mar 05 04:52 PM
Crystal Adam	President, R&D	Feb 25 '26	Sale	12.77	54,345	694,208	132,873	Feb 27 06:54 PM
ADAM CRYSTAL	Officer	Feb 25 '26	Proposed Sale	12.88	54,345	699,964		Feb 25 04:36 PM
Beckman Daniella	Chief Financial Officer	Feb 03 '26	Sale	12.26	10,317	126,531	184,297	Feb 04 08:12 PM
Weber Barbara	Director, Executive Chair	Feb 03 '26	Sale	12.26	30,519	374,294	1,629,254	Feb 04 08:09 PM
Crystal Adam	President, R&D	Feb 03 '26	Sale	12.26	18,452	226,300	187,218	Feb 04 08:02 PM
Third Rock Ventures IV, L.P.	10% Owner	Oct 23 '25	Sale	10.15	477,401	4,846,575	13,386,574	Oct 27 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Oct 23 '25	Proposed Sale	7.53	477,401	3,594,830		Oct 23 05:10 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 25 '25	Sale	8.02	500,000	4,008,500	13,863,975	Sep 29 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 25 '25	Proposed Sale	7.80	500,000	3,900,000		Sep 25 04:58 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 16 '25	Sale	7.04	363,541	2,559,329	14,363,975	Sep 17 06:06 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 16 '25	Proposed Sale	7.35	363,541	2,672,026		Sep 17 10:29 AM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '25	Sale	7.00	642,906	4,500,342	14,813,975	Sep 09 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 08 '25	Sale	7.04	86,459	608,628	14,727,516	Sep 09 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 08 '25	Proposed Sale	7.04	86,459	608,628		Sep 08 05:22 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '25	Proposed Sale	6.94	642,906	4,461,767		Sep 05 06:08 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 22 '25	Sale	7.00	302,194	2,115,358	15,456,881	Aug 26 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 22 '25	Proposed Sale	6.90	302,194	2,085,139		Aug 22 05:26 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '25	Sale	7.01	1,100,000	7,712,760	15,759,075	Aug 21 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '25	Proposed Sale	6.96	1,100,000	7,656,000		Aug 19 07:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNGX

Tango Therapeutics Inc

Upgrade your Finviz experience